George Frey | Bloomberg | Getty Photography
Weight reduction medication exploded into the public sight this yr, and 2024 will bring more replace to the evolving market.
The medication skyrocketed in fame in 2023 as they helped sufferers shed important weight, irrespective of hefty heed tags, mixed insurance coverage coverage and a handful of execrable aspect outcomes.
Inquire of for the medication is now potentially to not unhurried down in 2024, especially as treatments progressively turned into more accessible. Considerable of Wall Avenue believes the burden loss drug market will easiest develop, with some analysts projecting that this would possibly perchance be rate $100 billion by the ruin of the final decade. Goldman Sachs analysts place a question to 15 million U.S. adults to be on obesity medications by 2030.
But next yr, buyers will seemingly be staring at how the dominant players in the market, Novo Nordisk and Eli Lilly, navigate present problems plaguing their treatments. Patients had been struggling to fetch their hands on Novo Nordisk’s weight reduction injection Wegovy, its diabetes treatment Ozempic, and Eli Lilly’s diabetes injection Mounjaro.
Analysts place a question to present constraints to give a rob to but rate that the broader grief will take years to solve.
Exterior of present headwinds and the dearth of broader insurance coverage coverage for weight reduction medication, Novo Nordisk and Eli Lilly dangle an infinite yr earlier than them.
Novo Nordisk would possibly perchance uncover approvals for expanded consume of Wegovy in the U.S. and Europe. Eli Lilly’s newly licensed weight reduction drug, Zepbound, would possibly perchance garner more than a billion dollars in gross sales in its first yr on the market.
Both corporations are additionally anticipated to free up contemporary data that would possibly perchance reward other skill well being advantages of their medication past weight reduction and diabetes management, which would possibly perchance develop insurance coverage coverage down the dual carriageway.
Next yr would possibly perchance suggest even more to the opposite corporations hoping to affix what’s so a long way been a two-horse jog to perform weight reduction treatments.
Unusual drug data from Pfizer and Amgen, and the aptitude for more buyouts or collaborations between bigger corporations and smaller makers of obesity medication, would possibly perchance alter the market’s competitive landscape in the impending months.
Table of Contents
Offer problems would possibly perchance ease but would possibly perchance no longer bound away
The present problems plaguing Wegovy, Ozempic and Mounjaro are seemingly “the biggest teach” buyers will inquire next yr, Guggenheim analyst Seamus Fernandez urged CNBC.
Some analysts acknowledged present constraints will seemingly persist for years, but place a question to them to ease in 2024 as Novo Nordisk and Eli Lilly work to lengthen manufacturing capacity for their medication.
Novo Nordisk throughout its third-quarter earnings name in November acknowledged it is “attempting at tremendously scaling our present” of Wegovy in the U.S. in 2024. TD Cowen analyst Michael Nedelcovych urged CNBC that the corporate throughout the name looked as if it would suggest that this form of replace wouldn’t inquire love an infinite jump in present but quite precise enhancements over time.
Offer would possibly perchance develop more tremendously years from now: Novo Nordisk in November acknowledged it could perhaps well make investments $6 billion to lengthen its manufacturing companies and products in Denmark, noting this would possibly perchance attain constructing from the ruin of 2025 thru 2029. The company additionally acknowledged it could perhaps well spend round $2.3 billion to lengthen every other manufacturing effect in France.
High weight reduction and diabetes medication
Wegovy from Novo Nordisk is a weekly weight reduction injection for adults with obesity or who are obese. The drug mimics a hormone produced in the gut known as GLP-1 to suppress a particular person’s appetite.
Zepbound from Eli Lilly is a weekly weight reduction injection for adults with obesity or who are obese. The treatment mimics GLP-1 and every other gut hormone known as GIP to decrease appetite and food consumption.
Ozempic from Novo Nordisk is a weekly injection that helps decrease blood sugar ranges in adults with Kind 2 diabetes. The medication mimics GLP-1 to suppress appetite and abet the pancreas perform more insulin.
Mounjaro from Eli Lilly is a weekly injection that helps decrease blood sugar ranges in adults with Kind 2 diabetes. The drug mimics GLP-1 and GIP to curb appetite and stimulate insulin manufacturing.
Meanwhile, Eli Lilly acknowledged throughout its third-quarter earnings name in November that present of Mounjaro has improved in the U.S. even as it stays constrained world broad.
Executives additionally acknowledged that Eli Lilly is heading in the precise course to perform its aim of doubling manufacturing capacity for medication equivalent to Mounjaro, in portion thru investments in contemporary manufacturing net pages in North Carolina and Indiana.
But Eli Lilly CEO David Ricks acknowledged on the name that the corporate is “aggressively planning” additional manufacturing buildup for Mounjaro and other medication. He added that “it is a grief we work on each day. So we’re indubitably no longer delighted with the capacity.”
Zepbound would possibly perchance turned into a blockbuster
Wall Avenue has excessive hopes for Eli Lilly’s Zepbound, which is already on hand at U.S. pharmacies. Some analysts place a question to the medication to fetch blockbuster location next yr, which is when a treatment’s annual gross sales exceed $1 billion.
The FDA approves Eli Lilly’s Zepbound, a weight reduction drug equivalent to Ozempic and Wegovy.
Courtesy: Eli Lilly
Morgan Stanley expects Zepbound to rake in $2.2 billion in gross sales in 2024, in step with a rate launched after the drug’s approval in November. Meanwhile, Financial institution of America analysts in a November rate projected $2.7 billion in Zepbound earnings in 2024.
Some analysts place a question to a long way more gross sales growth for Zepbound and Mounjaro past 2024. Tirzepatide, the energetic ingredient in both medication, has a “very tough shot of being the absolute top-promoting molecule of all time in the pharmaceutical industry,” acknowledged Guggenheim’s Fernandez.
Wall Avenue is brooding about Zepbound in portion on memoir of it could perhaps perchance trigger more weight reduction than Wegovy. Review straight evaluating the two, including an ongoing trial from Eli Lilly, would prefer to confirm that.
Results from that trial would possibly perchance reach out next yr after initial data from separate stories inspecting Zepbound as a doable treatment for other well being stipulations, including heart failure.
Mixed insurance coverage coverage will seemingly weigh on gross sales of Zepbound and other weight reduction medication in 2024, but Eli Lilly has already secured some coverage for the drug.
Wegovy would possibly perchance perform history again
Wegovy made history this yr when it slashed the ache of extreme heart problems by 20% in other folks with obesity and heart illness in a slack-stage trial. In 2024, the drug would possibly perchance shake up the pharmaceutical industry again if U.S. and European regulators resolve to approve it for that aim.
These skill approvals, which would possibly well perform Wegovy the first GLP-1 drug to dangle an expanded consume for heart well being, are a “foregone conclusion” for Novo Nordisk, Cantor Fitzgerald’s Louise Chen urged CNBC.
Accumulated lifestyles of Wegovy an injectable prescription weight reduction medication that has helped other folks with obesity. It will peaceable be mature with a weight-reduction realizing and bodily narrate.
Michael Siluk | UCG | Getty Photography
An FDA approval would possibly perchance doubtlessly develop the uptake of Wegovy, encouraging more obesity consultants, essential care suppliers and cardiologists to prescribe it to eligible sufferers, acknowledged Dr. Eduardo Grunvald, scientific director for UC San Diego’s Center for Stepped forward Weight Administration.
An approval would possibly perchance additionally place more stress on U.S. insurers to sooner or later quilt Wegovy and the same weight reduction treatments, opening the door for broader consume.
Eli Lilly is additionally finding out the cardiovascular advantages of Zepbound in a portion three scientific trial in diabetes sufferers with elevated cardiovascular ache, and outcomes are anticipated in slack 2024. The drugmaker is conducting a the same sight in obese sufferers with heart-well being risks, but outcomes would possibly perchance no longer reach until 2027.
Meanwhile, Novo Nordisk’s other treatments would possibly perchance reach their agree with milestones next yr.
Novo Nordisk expects to free up data in the first half of 2024 from a slack-stage trial inspecting Ozempic as a treatment for kidney failure in diabetes sufferers with chronic kidney illness. The company hinted that the trial would be a success when it halted the sight a yr earlier than deliberate in October in step with an intervening time analysis.
Upcoming scientific trial data releases
- A portion-three trial from Eli Lilly on Zepbound as a treatment for cardiovascular complications in diabetes.
- A portion-three trial from Novo Nordisk on Ozempic as a treatment for kidney failure in diabetes sufferers with chronic kidney illness.
- A portion-three trial from Novo Nordisk on a 25-milligram version of its as soon as-a-day weight reduction tablet.
- A portion-three trial on Zepbound as a doable treatment for heart failure in sufferers with obesity.
- A portion-three trial on Zepbound as a doable treatment for non-alcoholic fatty liver illness, which is attributable to corpulent buildup in the liver, in sufferers with obesity.
- A portion-three trial on Zepbound as a doable treatment for obstructive sleep apnea, or the ruin of breathing throughout sleep on account of blocked airways, in sufferers with obesity.
- A portion-three trial on IcoSema, a combination of as soon as-weekly insulin and as soon as-weekly semaglutide, in sufferers with diabetes.
Novo Nordisk will additionally free up portion three scientific trial data on a 25-milligram version of its as soon as-a-day weight reduction tablet, which uses semaglutide, the same energetic ingredient as in Ozempic and Wegovy.
That trial is obligatory on memoir of Novo Nordisk is in a position to inquire that data sooner than submitting for approval of the oral weight reduction drug, acknowledged Cowen’s Nedelcovych. He added that in the very long time period, the availability of weight-loss capsules would possibly perchance enhance capacity for their injectable counterparts.
Additionally in 2024, a sight following sufferers from a old slack-stage trial would possibly perchance doubtlessly generate data supporting Wegovy as a treatment for scuffling with the trend of diabetes, Nedelcovych acknowledged.
A perform-or-destroy yr for Pfizer
Unusual data next yr will seemingly be obligatory to determining whether Pfizer gets a piece of the burden loss drug house. The stakes are excessive: CEO Albert Bourla has acknowledged the corporate hopes to snatch $10 billion of that market.
Pfizer axed a twice-day-to-day version of the absolute top obesity product in its pipeline earlier this month after sufferers taking the tablet misplaced important weight but had bother tolerating the drug in a mid-stage sight.
Now, the corporate is pinning its hopes on a as soon as-a-day version of the tablet, is named danuglipron, which it believes would possibly perchance trigger fewer damaging aspect outcomes. Pfizer acknowledged it expects to free up more data on that version of the drug in the first half of 2024, which will abet the corporate resolve whether to launch up a slack-stage sight on the tablet.
CFOTO | Future Publishing | Getty Photography
Nevertheless, some analysts dangle raised questions about whether the as soon as-a-day version will seemingly be more uncomplicated to tolerate.
“No matter ongoing work, tolerability peaceable looks to be an grief with the product, and it is a long way rarely hump to us why this would possibly perchance give a rob to” in a portion three trial or with a as soon as-day-to-day version, JPMorgan analyst Chris Schott acknowledged in a December rate.
Barclays analyst Carter Gould acknowledged in a December rate that it is “more and more apparent” that the corporate will prefer to inquire externally for an obesity treatment, whether that’s thru an acquisition or partnership, to snatch a slash of the burden loss drug market love it had hoped.
Meanwhile, upcoming data will conceal how extreme Amgen’s weight reduction drug portfolio is. In the first half of 2024, Amgen is slated to publish early stage trial data on an oral weight reduction medication.
In the 2d half of the yr, Amgen plans to free up mid-stage trial data on an injectable drug that helped trigger up to 14.5% weight loss after 12 weeks in an early sight.
Sight for buyouts and partnerships
Pfizer is no longer the absolute top company that would possibly perchance dangle the relieve of attempting externally for obesity medication.
Increased drugmakers mature acquisitions of smaller corporations, or partnerships with them, to slit out house in the burden loss drug market this yr. Extra corporations would possibly perchance deploy the blueprint next yr, analysts acknowledged.
“There are a bunch of other neat-cap pharmas on the checklist who would possibly perchance attain this,” acknowledged Cantor Fitzgerald’s Chen.
Swiss company Roche acknowledged earlier this month it could perhaps well aquire the privately held U.S. obesity drugmaker Carmot Therapeutics for $2.7 billion. AstraZeneca signed a licensing agreement with Chinese biotech company Eccogene to develop an obesity tablet.
Novo Nordisk and Eli Lilly dangle additionally snapped up smaller obesity drug corporations this yr to withhold their dominance in the market.
Most up-to-date weight reduction drug buyouts and partnerships
- Roche in December acknowledged this would possibly perchance aquire privately held obesity drugmaker Carmot Therapeutics for $2.7 billion.
- AstraZeneca in November acknowledged it signed a licensing agreement with Chinese biotech company Eccogene to develop an obesity tablet.
- Novo Nordisk in August acknowledged this would possibly perchance put the privately held obesity drugmaker Inversago Pharma for $1.08 billion.
- Novo Nordisk in August acknowledged this would possibly perchance put Embark Biotech, which develops obesity and diabetes medication, for up to $500 million.
- Eli Lilly in July acknowledged this would possibly perchance put privately held obesity drugmaker Versanis for $1.93 billion.
In a press free up to CNBC, Novo Nordisk acknowledged it has elevated its point of curiosity on “sourcing and elevating exterior innovation” to enhance its in-house merchandise and develop its drug pipeline, especially for diabetes, obesity, cardiovascular illness and uncommon blood disorders.
The company additionally acknowledged it is in the “elephantine differ of enterprise trend actions,” from acquisitions to partnerships on early or slack-stage merchandise, in terms of corporations with contemporary biological medication, contemporary skill treatment targets and contemporary mechanisms of movement, or how a drug works.
Chen acknowledged acquisitions or partnerships could be the absolute top formula for puny- to mid-cap weight reduction drugmakers to meet up with Eli Lilly and Novo Nordisk.
Some smaller corporations dangle indicated that they’re originate to the premise: Altimmune acknowledged Dec. 5 that it is attempting to search out companions to open and develop its experimental obesity drug pemvidutide.
Shares of Altimmune dangle jumped more than 140% since Nov. 30, when the corporate launched mid-stage trial data showing that its injectable drug ended in 15.6% weight reduction on sensible after 48 weeks.
Diverse smaller weight reduction drugmakers contain Structure Therapeutics, whose as soon as-day-to-day tablet helped obese or obese sufferers lose up to 10 kilos of weight on sensible after a month in an early-stage trial. The company is anticipated to say mid-stage trial data on its drug in diabetes sufferers this month and more outcomes on the tablet in sufferers with obesity early next yr, Guggenheim’s Fernandez current.
Accumulated, some bigger drugmakers would possibly perchance wait to inquire bigger and later-stage data from smaller corporations sooner than transferring to put them. That data would possibly perchance no longer reach out until 2025 or later for many corporations, acknowledged Fernandez.
